ReviewClinical immunology (Orlando, Fla.)2013
Targeting the trimolecular complex.
Review in Clinical immunology (Orlando, Fla.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Rationally designed small molecules to prevent type 1 diabetes.Current opinion in endocrinology, diabetes, and obesity · 2019Review
- Prediction and prevention of type 1 diabetes in children.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2019Article
- Determining Antigen Specificity of Human Islet Infiltrating T Cells in Type 1 Diabetes.Frontiers in immunology · 2019Review
- CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.JCI insight · 2018Article
- Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes.Current diabetes reports · 2016Review
- Positive evidence for vitamin A role in prevention of type 1 diabetes.World journal of diabetes · 2016Review
- Molecular Interactions Governing Autoantigen Presentation in Type 1 Diabetes.Current diabetes reports · 2015Review
- Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at prevention.Pediatric diabetes · 2015Review
- Age-related obesity and type 2 diabetes dysregulate neuronal associated genes and proteins in humans.Oncotarget · 2015Article
- Type 1 diabetes: A predictable disease.World journal of diabetes · 2015Review
- Immunogenetics of type 1 diabetes mellitus.Molecular aspects of medicine · 2015Review
- Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention.Diabetes technology & therapeutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Class II major histocompatibility molecules (MHC) confer disease risk for multiple autoimmune disorders including type 1 diabetes. The interaction between the components of the trimolecular complex (CD4(+) T cell receptors, self-peptide, and MHC class II molecules) plays a pivotal role in autoimmune disease pathogenesis. The development of therapies targeting various components of the trimolecular complex for the prevention of type 1 diabetes is actively being pursued. This review focuses on the components of the anti-insulin trimolecular complex, registers of insulin peptide binding to 'diabetogenic' MHC class II molecules, and therapies targeting each component of the trimolecular complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.